Microbio Co Ltd (4128) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Microbio Co Ltd (4128) has a cash flow conversion efficiency ratio of 0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$233.22 Million ≈ $7.35 Million USD) by net assets (NT$9.92 Billion ≈ $312.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4128 market cap overview for the company's overall valuation and market capitalisation.
Microbio Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Microbio Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Microbio Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Microbio Co Ltd ranked by their cash flow conversion efficiency. Explore 4128 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Keyfield International Berhad
KLSE:5321
|
0.117x |
|
Dharma Polimetal Tbk PT
JK:DRMA
|
0.063x |
|
Compucase Enterprise Co Ltd
TW:3032
|
0.180x |
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
0.027x |
|
Hefei Jingsong Intelligent Technology Co. Ltd. A
SHG:688251
|
N/A |
|
Hongda High-Tech Holding Co Ltd
SHE:002144
|
0.004x |
|
Orient Cement Limited
NSE:ORIENTCEM
|
-0.027x |
|
Novabase SGPS
LS:NBA
|
0.059x |
Annual Cash Flow Conversion Efficiency for Microbio Co Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Microbio Co Ltd from 2006 to 2025. View 4128 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$10.20 Billion ≈ $321.50 Million |
NT$85.27 Million ≈ $2.69 Million |
0.008x | -81.28% |
| 2024-12-31 | NT$11.87 Billion ≈ $373.94 Million |
NT$529.90 Million ≈ $16.69 Million |
0.045x | +871.28% |
| 2023-12-31 | NT$13.50 Billion ≈ $425.34 Million |
NT$-78.15 Million ≈ $-2.46 Million |
-0.006x | -157.28% |
| 2022-12-31 | NT$14.01 Billion ≈ $441.34 Million |
NT$141.57 Million ≈ $4.46 Million |
0.010x | +159.17% |
| 2021-12-31 | NT$13.84 Billion ≈ $436.15 Million |
NT$53.98 Million ≈ $1.70 Million |
0.004x | -54.37% |
| 2020-12-31 | NT$12.85 Billion ≈ $404.91 Million |
NT$109.82 Million ≈ $3.46 Million |
0.009x | +6.78% |
| 2019-12-31 | NT$9.04 Billion ≈ $284.89 Million |
NT$72.36 Million ≈ $2.28 Million |
0.008x | +388.65% |
| 2018-12-31 | NT$9.68 Billion ≈ $304.91 Million |
NT$15.85 Million ≈ $499.33K |
0.002x | +238.29% |
| 2017-12-31 | NT$8.30 Billion ≈ $261.53 Million |
NT$-9.83 Million ≈ $-309.70K |
-0.001x | +94.47% |
| 2016-12-31 | NT$8.41 Billion ≈ $265.04 Million |
NT$-180.25 Million ≈ $-5.68 Million |
-0.021x | -18.36% |
| 2015-12-31 | NT$8.94 Billion ≈ $281.77 Million |
NT$-161.90 Million ≈ $-5.10 Million |
-0.018x | +1.39% |
| 2014-12-31 | NT$9.10 Billion ≈ $286.68 Million |
NT$-167.04 Million ≈ $-5.26 Million |
-0.018x | +9.53% |
| 2013-12-31 | NT$8.70 Billion ≈ $274.25 Million |
NT$-176.63 Million ≈ $-5.56 Million |
-0.020x | +3.13% |
| 2012-12-31 | NT$6.32 Billion ≈ $199.08 Million |
NT$-132.36 Million ≈ $-4.17 Million |
-0.021x | +51.99% |
| 2011-12-31 | NT$6.23 Billion ≈ $196.39 Million |
NT$-271.95 Million ≈ $-8.57 Million |
-0.044x | -142.24% |
| 2010-12-31 | NT$5.04 Billion ≈ $158.75 Million |
NT$520.41 Million ≈ $16.40 Million |
0.103x | +211.97% |
| 2009-12-31 | NT$5.26 Billion ≈ $165.69 Million |
NT$-485.10 Million ≈ $-15.28 Million |
-0.092x | -15.56% |
| 2008-12-31 | NT$1.79 Billion ≈ $56.53 Million |
NT$-143.21 Million ≈ $-4.51 Million |
-0.080x | -8.41% |
| 2007-12-31 | NT$1.29 Billion ≈ $40.78 Million |
NT$-95.30 Million ≈ $-3.00 Million |
-0.074x | -1038.56% |
| 2006-12-31 | NT$559.40 Million ≈ $17.62 Million |
NT$4.39 Million ≈ $138.25K |
0.008x | -- |
About Microbio Co Ltd
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and health foods in Taiwan. It provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. The company is also involved in the sale of organic food and beverages; provision of te… Read more